# Phase IIa Clinical Study of N-Rephasin® SAL200

> **NCT03089697** · PHASE2 · TERMINATED · sponsor: **Intron Biotechnology, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Staphylococcus Aureus Bacteremia
- Anti-Bacterial Agents

## Interventions

- **BIOLOGICAL:** N-Rephasin® SAL200
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03089697
- **Lead sponsor:** Intron Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-07
- **Primary completion:** 2019-11-07
- **Final completion:** 2019-11-07
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Enrollment into this study was terminated by the Sponsor prior to completion for strategic reasons.
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03089697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03089697, "Phase IIa Clinical Study of N-Rephasin® SAL200". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03089697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*